Risk factor
Very high price volatility
Profitability factor
Overvalued vs peers
About
Based in New Taipei City, China, 3D Global Biotech Inc. (3DGBI) specializes in the development of advanced medical materials designed for human body reconstruction. The company leverages sophisticated cell culture systems, cutting-edge 3D printing technology, and proprietary bio-inks hydrogel to create personalized, patient-specific cell-based medical products. Beyond product manufacturing, 3DGBI is dedicated to building platforms for human tissue and organ regeneration, engineering customized medical equipment, and undertaking significant professional research. Its extensive product range includes artificial bone substitutes, skull fixation systems, biological dressings, bio-inks, and bioprinting machinery. They also offer specialized solutions for orthopedic, dental, cranial, and scalp reconstruction. The company serves a broad spectrum of clients, including medical centers, research institutions, businesses, and distributors. 3DGBI actively fosters an interdisciplinary alliance, bringing together expertise from industry, government, academia, research, and medicine. It was established in 2014.
Company Valuation
Based on key historical and expected multiples, the stock is overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA, rea